Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis.
chemotherapy
gastric acid suppressant
proton pump inhibitors
tyrosine kinase inhibitors
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 Apr 2020
18 Apr 2020
Historique:
received:
29
03
2020
revised:
04
04
2020
accepted:
14
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
4
2020
Statut:
epublish
Résumé
We performed a systematic review and meta-analysis to evaluate the role of gastric acid suppressant use on outcomes of tyrosine kinase inhibitors (TKIs) and oral chemotherapy. We identified all research evaluating the effect of GAS (gastric acid suppressants) use on patients receiving oral chemotherapy or TKIs for solid tumors. The pooled hazard ratios (HRs) and 95% confidence interval (95%CI) for overall survival (OS) and progression-free survival (PFS) were calculated with a fixed-effects or a random effects model. The study population included
Identifiants
pubmed: 32325628
pii: cancers12040998
doi: 10.3390/cancers12040998
pmc: PMC7226385
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
JAMA Oncol. 2017 Jun 1;3(6):767-773
pubmed: 27737436
J Clin Pharmacol. 2018 Apr;58(4):474-484
pubmed: 29178442
J Clin Oncol. 2016 Apr 20;34(12):1309-14
pubmed: 26858332
Lancet Oncol. 2013 Dec;14(13):1287-94
pubmed: 24206640
Nouv Rev Fr Hematol. 1989;31(2):77-84
pubmed: 2671933
Eur J Cancer. 1993;29A(7):940-2
pubmed: 8499146
Onco Targets Ther. 2019 Jul 09;12:5467-5484
pubmed: 31371986
Ther Drug Monit. 2018 Dec;40(6):699-704
pubmed: 29995672
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
JAMA. 2000 Apr 19;283(15):2008-12
pubmed: 10789670
Clin Lung Cancer. 2015 Jan;16(1):33-9
pubmed: 25246385
Mol Clin Oncol. 2014 Jan;2(1):116-120
pubmed: 24649318
Clin Cancer Res. 2019 Mar 1;25(5):1479-1485
pubmed: 30765389
Curr Opin Endocrinol Diabetes Obes. 2014 Feb;21(1):3-8
pubmed: 24310148
Stat Med. 2002 Jun 15;21(11):1539-58
pubmed: 12111919
J Clin Pharmacol. 2018 Feb;58(2):263-268
pubmed: 28981161
Eur J Intern Med. 2017 Jan;37:19-24
pubmed: 27784575
J Clin Oncol. 2010 Feb 20;28(6):1061-8
pubmed: 20100962
Clin Lung Cancer. 2016 Sep;17(5):412-418
pubmed: 26944770
Clin Colorectal Cancer. 2016 Sep;15(3):257-63
pubmed: 26803708
J Oncol Pharm Pract. 2015 Jun;21(3):194-200
pubmed: 24664477
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
Clin Colorectal Cancer. 2019 Mar;18(1):72-79
pubmed: 30551953
Br J Clin Pharmacol. 2009 Sep;68(3):370-4
pubmed: 19740393
Int J Cancer. 2018 Sep 15;143(6):1315-1326
pubmed: 29658114
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Curr Oncol. 2016 Dec;23(6):e583-e588
pubmed: 28050148
Cancer Chemother Pharmacol. 2017 Dec;80(6):1171-1178
pubmed: 29051995
Cancer Chemother Pharmacol. 2012 Sep;70(3):399-405
pubmed: 22806307
Clin Pharmacol Ther. 2012 Aug;92(2):203-13
pubmed: 22739140
Br J Cancer. 1998;78 Suppl 3:1-7
pubmed: 9717984
Oncologist. 2018 Jun;23(6):686-692
pubmed: 29487220
Cancer Manag Res. 2019 Sep 19;11:8539-8546
pubmed: 31572008
Am J Gastroenterol. 2007 May;102(5):942-50
pubmed: 17313495
Clin Genitourin Cancer. 2017 Dec;15(6):724-732
pubmed: 28645482
Oncotarget. 2016 Dec 20;7(51):85542-85550
pubmed: 27907909
World J Gastroenterol. 2017 Apr 14;23(14):2575-2584
pubmed: 28465642
Br J Cancer. 2014 Nov 11;111(10):1909-16
pubmed: 25349968
Stat Med. 1998 Dec 30;17(24):2815-34
pubmed: 9921604
Cancer. 2019 Apr 1;125(7):1155-1162
pubmed: 30605231
Lancet Oncol. 2012 Mar;13(3):239-46
pubmed: 22285168
Lung Cancer. 2013 Oct;82(1):136-42
pubmed: 23910908
PLoS One. 2016 Feb 19;11(2):e0149722
pubmed: 26894507